Deliver a professional weight loss service through Scripter's structured consultation pathway. Supply: Tirzepatide (Mounjaro) pre-filled injection pens, titrated dosing.

Book a demo Browse all PGDs

What is Mounjaro (tirzepatide)?

Mounjaro is once-weekly tirzepatide, a dual GIP and GLP-1 receptor agonist. Acting on two incretin pathways at once, it produced the largest average weight losses yet seen in trials, exceeding 20% at higher doses.

The condition it treats

Obesity treatment with dual-agonist therapy follows the same clinical architecture as other GLP-1 services: criteria in, titration through, reviews always, with the added counselling weight of a newer molecule.

How the service runs on Scripter

Patients book online, complete the pre-consultation questionnaire, and the guided pathway walks the practitioner through the weight loss consultation with the screening and counselling steps built in. The supply decision, the record and any GP notification are produced in the same flow, documented against the exact protocol version in force.

Training and eligibility requirements.

Who can deliver this service, and who it can be delivered to. The governing PGD document defines the definitive inclusion, exclusion and supply criteria; the Scripter consultation pathway enforces them, and every consultation is documented against the protocol version it ran under.

Practitioner training

✓Registered healthcare professional from a profession authorised to supply under PGDs (Schedule 16, Part 4 of the Human Medicines Regulations 2012), such as a pharmacist, nurse, paramedic or physiotherapist, with current registration with their professional regulator

✓Practising from premises suitable for the service, such as registered pharmacy premises or a registered clinic

✓Assessed clinical competency for this service, declared and reviewed as part of PGD authorisation

✓Sign-off against the current version of this PGD in Scripter before first supply; sign-offs expire automatically when the protocol is updated, and the platform notifies everyone affected

✓In-date basic life support and safeguarding training

✓Indemnity arrangements covering the service

✓Face-to-face injection technique training for the relevant route

✓In-date anaphylaxis recognition and management training, with adrenaline available on site

✓Vaccine storage and cold-chain procedures in place where the service supplies vaccines

Patient eligibility

✓Adults meeting the governing PGD's BMI and comorbidity criteria

✓Pregnancy excluded; oral contraceptive efficacy counselling included (tirzepatide can reduce it around dose steps)

✓Thyroid carcinoma, MEN2 and pancreatitis history screened out

✓Face-to-face injection training and titration schedule enforced by the pathway

Mounjaro (tirzepatide) PGD questions

How is Mounjaro different from Wegovy?+

Tirzepatide stimulates both GIP and GLP-1 receptors and averaged greater weight loss in trials; suitability still comes down to the individual consultation and the governing PGD's criteria.

Why does the pathway mention contraception specifically?+

Tirzepatide can blunt oral contraceptive absorption around initiation and dose increases; the counselling step covers additional precautions at those points.

What monitoring continues after starting?+

Weight, tolerability and side effects on the PGD's review schedule, tracked as health metrics on the record so progress is a chart, not a memory.

More weight loss PGDs.

Related protocols in the same category, all delivered through the same platform.

Run a weight loss service without the paperwork.

See the consultation pathway, the sign-off tracking and the record it produces in a free 30-minute demo.

Book a demo Contact us

Built for pharmacists, by pharmacists.